期刊文献+

生理能力与手术应激评分系统和改良的生理能力与手术应激评分系统在预测胃癌术后死亡率和手术风险中的价值 被引量:12

Value of E-PASS and mE-PASS in predicting morbidity and mortality of gastric cancer surgery
原文传递
导出
摘要 目的:探讨生理能力与手术应激评分系统( E-PASS)和改良的生理能力与手术应激评分系统( mE-PASS)预测胃癌患者术后死亡率的价值及其相关参数与术后并发症的关系。方法收集2010年l月至2014年1月行手术切除的778例胃癌患者的临床资料,应用E-PASS和mE-PASS评分系统预测胃癌患者术后的死亡率,应用受试者工作特征( ROC)曲线和拟合优度检验评价E-PASS和mE-PASS评分系统预测术后死亡率的效率,应用非条件Logistic回归分析评价E-PASS评分系统的相关参数与胃癌患者术后并发症的关系。结果 E-PASS和mE-PASS评分系统预测死亡组和非死亡组的死亡率差异均有统计学意义(均P<0.05)。 E-PASS和mE-PASS评分系统预测胃癌术后死亡率风险的ROC曲线下面积分别为0.926和0.878。 E-PASS和mE-PASS评分系统预测胃癌患者术后死亡率的ROC曲线拟合优度检验差异均无统计学意义(均P>0.05)。单因素分析显示,年龄、手术时间、严重心脏病、严重肺病、糖尿病、体能状态分级和美国麻醉医师协会( ASA)分级为影响胃癌患者术后早期并发症的因素(均P<0.05);非条件Logistic回归分析结果显示,糖尿病、严重肺病、ASA分级和手术时间为影响胃癌患者术后并发症的独立因素(均P<0.05)。结论 E-PASS和mE-PASS评分系统预测胃癌患者术后死亡率与实际死亡率具有较好的一致性,均适用于临床。与E-PASS评分系统比较, mE-PASS评分系统简化了术中参数。严重肺病、糖尿病、手术时间和ASA分级为影响胃癌患者术后并发症的独立危险因素。 Objective To investigate the clinical value of Physiologic Ability and Surgical Stress ( E-PASS) and modified Estimation of Physiologic Ability and Surgical Stress ( mE-PASS) scoring systems in predicting the mortality and surgical risk of gastric cancer patients, and to analyze the relationship between the parameters of E-PASS and early postoperative complications. Methods Clinical data of 778 gastric cancer patients who underwent elective surgical resection in Tianjin Medical University General Hospital from Jan. 2010 to Jan. 2014 were analyzed retrospectively. E-PASS and mE-PASS scoring systems were used to predict the mortality of gastric cancer patients, respectively. Univariate and unconditioned logistic regression analyses were performed to assess the relationships between nine parameters of E-PASS system and early postoperative complications. Results E-PASS and mE-PASS systems were used to predict the mortality in the death group and non-death group. The Z value was -5. 067 and -4. 492, respectively, showing a significant difference between the two groups (P〈0.05). AUCs of mortality predicted by E-PASS and mE-PASS were 0.926 and 0.878 (P>0.05), and the prediction calibration of postoperative mortality showed statistically non-significant difference (P〉0.05) between the E-PASS and mE-PASS prediction and actual mortality. Univariate analysis showed that age, operation time, severe heart disease, severe lung disease, diabetes mellitus, physical state index and ASA classification score are related to postoperative complications 〈br〉 ( P〈0. 05 for all ) . Unconditioned logistic regression analysis showed that severe lung disease, diabetes mellitus, ASA classification score and operation time are risk factors for early postoperative complications ( P〈0.05 for all) . Conclusions Both mE-PASS and E-PASS scoring system have good consistency in the predicting postoperative mortality and actual mortality, and both are suitable for clinical application. Moreover, the mE-PASS scoring system is clinically more simple and convenient than E-PASS scoring system. Preoperative severe lung disease, diabetes mellitus, ASA classification score and operation time are independent factors affecting the early postoperative complications.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2015年第10期753-758,共6页 Chinese Journal of Oncology
关键词 胃肿瘤 死亡率 手术后并发症 生理能力与手术应激评分系统 改良生理能力与手术应激评分系统 Stomach neoplasms Mortality Postoperative complications Estimation of physiologic ability and surgical stress Modified estimation of physiologic ability and surgical stress
  • 相关文献

参考文献30

  • 1陈万青,郑荣寿,曾红梅,张思维,赵平,赫捷.1989-2008年中国恶性肿瘤发病趋势分析[J].中华肿瘤杂志,2012,34(7):517-524. 被引量:202
  • 2庄庆昕,徐建明,林莉,葛飞娇,刘烈军,王岩,赵传华.636例胃癌患者临床治疗现状分析[J].中华肿瘤杂志,2012,34(4):316-320. 被引量:21
  • 3Haga Y, Ikei S, Ogawa M. Estimation of Physiologic Ability and Surgical Stress (E-PASS) as a new prediction scoring system for postoperative morbidity and mortality following elective gastrointestinal surgery [ J 1. Surg Today, 1999, 29 ( 3 ) : 219-225.
  • 4Haga Y, Wada Y, Takeuchi H, et al. Evalumion of modified Estimation of Physiologic Ability and Surgical Stress in gastric carcinoma surgery [J]. Gastric Cancer, 2012, 15( 1 ) :7-14.
  • 5Haga Y, Wada Y, Ikenaga M, et al. Evaluation of modified estimation of physiologic abihty and surgical stress in colorectal carcinoma surgery[J]. Dis Colon Rectum, 2011, 54(10) : 1293-1300.
  • 6Haga Y, Wada Y, Takeuchi H, et al. Evaluation of modified estimation of physiologic ability and surgical stress in patients undergoing surgery for choledochocystolithiasis [ J ]. World J Surg, 2014, 38 (5) :1177-1183.
  • 7Russell SD, Saval MA, Robbins JL, et al. New York Heart Association functional class predicts exercise parameters in the current era[ J]. Am Heart J, 2009, 158(4 Suppl) :$24-30.
  • 8Haga Y, Wada Y, Takeuchi H, et al. Estimation of physiologic ability and surgical stress (E-PASS) for a surgical audit in elective digestive surgery[J]. Surgery, 2004, 135(6) :586-594.
  • 9Alberti KG, Zintn PZ. Definition, diagrsis and classification of diabetes mellitus and its complications. Part 1 : diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [ J ]. Diabet Med, 1998, 15(7) :539-553.
  • 10Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oneology Group[ J]. Am J Clin Oncol, 1982, 5(6) :649-655.

二级参考文献34

  • 1赫捷,赵平,陈万青.2011中国肿瘤登记年报.北京:军事医学科学出版社,2011:20-23.
  • 2Jensen OM, Parkin DM, Maclennan R, et al. Cancer registration principles and methods. IARC Sci Pub No. 95. Lyon: IARC, 1991:101-107.
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. Lyon: IARC, 1994:35-49.
  • 4Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19 : 335-351.
  • 5Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 2012, 118:2338-2366.
  • 6Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions ( risk factors, screening, and treatment) to reduce future rates. Cancer, 2010, 116:544- 573.
  • 7Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population- based trends in cancer treatment. J Natl Cancer Inst, 2005, 97 : 1407-1427.
  • 8Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U. S. cancer burden. Cancer; 2002, 94: 2766-2792.
  • 9Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst, 2008, 100: 1672-1694.
  • 10Dindo D, Demartines N, Clavien PA, et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg,20(O ,240:205-213.

共引文献233

同被引文献110

  • 1黎勇林,唐正严,齐琳,陈志,李东杰,曾铭强,薛睿智,彭川.前列腺癌穿刺活组织检查阳性率影响因素的分析及前列腺癌预测模型的建立[J].中南大学学报(医学版),2015,40(6):651-656. 被引量:8
  • 2Farazi T A, Spitzer J I, Momzov P, et al. miRNAs in human cancer [J]. J Pathol, 2011,223(2) : 102-115.
  • 3Nikitina E G, Urazova L N, Stegny V N. mieroRNAs and human cancer[J]. Exp Oncol, 2012, 34(1) : 2 -8.
  • 4Mahgouh A, Steer C J. microRNAs in the evaluation and potential treatment of liver diseases[ J/OL]. J Clin Med, 2016, 5(5) : E52. doi: 10. 3390/jcm5050052.
  • 5Li Y, Zu L, Wang Y, et al. miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4[ J]. J Thorae Dis, 2015, 7(9) : 1563 -1569.
  • 6Mahn R, Heukamp L C, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer [ J/OL ]. Urology, 2011, 77 (5): 1265. e9 - 16. doi: 10. 1016/ j. urology. 2011.01. 020.
  • 7Li C Y, Liang G Y," Yao W Z, et al. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression[J]. Clin Transl Oncol, 2016 May 12. [Epub ahead of print ].
  • 8Gulyaeva L F, Kushlinskiy N E. Regulatory mechanisms of microRNA expression[J/OL]. J Transl Med, 2016, 14 (1) : 143. doi: 10. 1186/s12967 - 016 - 0893 - x.
  • 9Yoshida K, Sugimoto N, lwahori S, et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher enkaryotic cells[J]. J Cell Sci, 2010, 123(2) : 225 -235.
  • 10Xiong X D, Fang J H, Qiu F E, et al. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma[J]. Mut Res, 2008, 643(1): 70-74.

引证文献12

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部